Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Pfizer discontinued US distribution of spectinomycin (Trobicin®) in November 2005; remaining inventory expired in May 2006 [1]. Nonetheless, at the FDA website we still find a Package Insert for Trobicin updated as late as Aug 2012, a thin 6-page leaflet which Continue reading The CDC and Spectinomycin
Besides ceftriaxone (CTRIAX), cefixime and spectinomycin we have no other highly effective single-dose treatment regimens for urogenital GC. Failures of all 3 drugs have been described but remain rare, can be overcome with higher doses of CTRIAX (1 g instead Continue reading GC Therapy – Shooting for the Stars
Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg [1]. In Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1)
The treatment history of N. gonorrhoeae makes for fascinating reading. This organism has always been able to keep the upper hand in the war of bug versus drug. Once susceptible to sulfa drugs, to penicillin, tetracyclines and fluoroquinolones, it sequentially Continue reading A GO / NO GO decision: Delafloxacin Stumbles in Gonorrhea Study